“I am excited for this interview. The open ended
Post# of 151522
Careful, these type of assumptions got a lot of investors hopes up over the past couple of weeks. I’d say the interview will reinforce what Dr. BP has said in the past and maybe a few nuggets on the paper. Besides that, he isn’t able to discuss any deductions he has made from reviewing the samples from the mild/mod and severe trials because I don’t think the FDA would like that.

